Mechanism of Duanteng Yimutang in Treating Rheumatoid Arthritis Based on Network Pharmacology Approach
10.13422/j.cnki.syfjx.20192404
- VernacularTitle: 基于网络药理学探讨断藤益母汤治疗类风湿关节炎的作用机制
- Author:
Qiang WANG
1
;
Min-ying LIU
2
;
Long-yin HAN
1
;
Wen-jie GUO
1
;
Xiao-bao LIU
1
;
Dong-mei PAN
3
;
Nan LI
4
;
Chang-song LIN
2
Author Information
1. The First Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, China
2. The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou 510405, China
3. School of Traditional Chinese Medicine(TCM), Southern Medical University, Guangzhou 510405, China
4. School of TCM, Ji'nan University, Guangzhou 510405, China
- Publication Type:Research Article
- Keywords:
Duanteng Yimutang;
rheumatoid arthritis;
network pharmacology;
inflammatory factor;
cytokine;
signal pathway
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2019;25(24):150-158
- CountryChina
- Language:Chinese
-
Abstract:
Objective:Duanteng Yimutang(DTYMT) has a significant effect in treating rheumatoid arthritis, but its composition is complex and its mechanism is not clear. It is worthwhile to use network pharmacology approach to find active components, therapeutic targets and signal pathways of DTYMT. Method:The drug composition was selected according to the pharmacokinetic parameters in the pharmacology database, the analysis platform (TCMSP) and the TCM integrated database (TCMID) of the Traditional Chinese Medicine System. The drug and disease targets were excavated in the Drugbank database and the Therapeutic Target Database (TTD), and the drug-target-pathway network was constructed by network pharmacology tool Cytoscap, in order to explore the mechanism of the action of the components in the DTYMT. Result:It was found that 11 effective components of DTYMT could target 42 proteins in rheumatoid arthritis, such as interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor (TNF), cyclooxygenase-2 (COX2), matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-3 (MMP-3), and inducible nitric oxide synthase (NOS2). Various pathways, including tumor necrosis factor (TNF) signaling pathway, interleukin-17 (IL-17) pathway, helper T cell 17 (Th17) differentiation pathway, rheumatic arthritis pathway, nuclear factor κB (NF-κB) pathway, osteoclast differentiation pathway, and ovarian steroid production pathway, were involved. Conclusion:DTYMT may be used to regulate inflammatory cytokines mainly through multiple inflammatory-related signal pathways, so as to play anti-inflammatory and immunoregulatory roles in the treatment of rheumatoid arthritis.
